Immune Cell Therapy Using mRNA and Immune Boosters Delivered Together

In situ CAR-macrophage therapy demonstrates robust CAR expression directly within the tumor microenvironment.

• Codelivery of mRNA and an immunostimulant using lipid nanoparticles facilitates direct targeting of tumor-associated macrophages.
• This method avoids the limitations of ex vivo manipulation, which can hinder gene transfer and macrophage phenotype maintenance.
• The addition of a stimulator of interferon genes (STING) agonist enhances local immune activation.
• In a mouse melanoma model, the approach reinforces CAR-macrophage functionality and improves antitumor effects.
• The findings indicate potential for an LNP-enabled strategy to address challenges faced by traditional CAR-T cell therapies.

Simplified